Publications

• October 15, 2015
  

  Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines

  Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D’Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clin Infectious Dis. 2015;61(suppl 3):S102–18.

• October 15, 2015
  

  Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done

  Schito M, Maeurer M, Kim P, Hanna D, Zumla A. Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done. Clin Infectious Dis. 2015;61(suppl 3):S95–101.

• October 13, 2015
  

  Considerations for Requiring Subjects to Provide a Response to Electronic Patient-Reported Outcome Instruments

• October 1, 2015
  

  A Collaborative Approach for “ReSeq-Ing” Mycobacterium Tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers

  Schito M, Dolinger DL. A Collaborative Approach for “ReSeq-Ing” Mycobacterium Tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers. EBioMedicine. 2015 Oct;2(10):1262–5.

• October 1, 2015
  

  Global Collaboration to Develop New and Existing Drugs for Neonates

  Davis JM, Turner MA. Global Collaboration to Develop New and Existing Drugs for Neonates. JAMA pediatrics. 2015 Oct;169(10):887–8.